# US 2016/0250197 A1 · An inhalable medicament

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250197 A1
- Document ID: US20160250197A1
- Status: Published application
- Kind: A1
- Application number: 14/419,803
- Filed: 2014-11-21
- Published: 2016-09-01
- Earliest claimed: 2013-11-22
- Assignees: Teva Branded Pharmaceutical Products R&D, Inc.
- Applicants: Teva Branded Pharmaceutical Products R&D, Inc.
- Inventors: Mukul Dalvi; Libo Wu
- Web page: https://patentgrep.com/patent/US20160250197A1

## CPC

- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61M 11/00: Sprayers or atomisers specially adapted for therapeutic purposes (in general B05B; {aerosol containers B65D83/14})
- A61M 15/0021: {Mouthpieces therefor}
- A61M 15/009: {using medicine packages with incorporated spraying means, e.g. aerosol cans (pocket atomiser of the injector type A61M11/08)}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Accordingly, the present invention provides a solution formulation for inhalation comprising: a liquid phase; an active ingredient having a functional group which is susceptible to hydrolysis and/or solvolysis, dissolved in the liquid phase; and a magnesium or calcium salt, dissolved in the liquid phase. The formulation is particularly suited to pMDIs and nebulisers.

## Claims

### Claim 1

A solution formulation for inhalation comprising:
a liquid phase;
an active ingredient having a functional group which is susceptible to hydrolysis and/or solvolysis, dissolved in the liquid phase; and
at least one of a magnesium or calcium salt, dissolved in the liquid phase.

### Claim 2 (depends on 1)

The formulation as claimed in claim 1, wherein the functional group is a carboxylic ester.

### Claim 3 (depends on 1)

The formulation as claimed in claim 1, wherein the active ingredient contains a carboxylic ester in which the oxygen atom is covalently bound to a quaternary nitrogen-containing heterocycle.

### Claim 4 (depends on 1)

The formulation as claimed in claim 1, wherein the amount of active ingredient is from 0.001-0.4 wt %, based on the total weight of the formulation.

### Claim 5 (depends on 1)

The formulation as claimed in claim 1, wherein the salt includes at least one of magnesium chloride, magnesium citrate, calcium chloride calcium citrate.

### Claim 6 (depends on 1)

The formulation as claimed in claim 1, wherein the amount of salt is from 0.0001 to 0.01 wt %, based on the total weight of the formulation.

### Claim 7 (depends on 1)

The formulation as claimed in claim 1, wherein the formulation is for a pressurised metered dose inhaler and the liquid phase comprises an HFA propellant.

### Claim 8 (depends on 7)

The formulation as claimed in claim 7, wherein the liquid phase additionally comprises a co-solvent.

### Claim 9 (depends on 8)

The formulation as claimed in claim 8, wherein the co-solvent comprises ethanol.

### Claim 10 (depends on 9)

The formulation as claimed in claim 9, wherein the formulation comprises tiotropium bromide, ethanol, glycerol, water, citric acid, magnesium chloride and an HFA propellant.

### Claim 11 (depends on 1)

The formulation as claimed in claim 1, wherein the formulation is for a nebuliser and the liquid phase comprises water.

### Claim 12 (depends on 1)

A metered dose inhaler comprising a canister, wherein the canister contains the formulation as claimed in claim 1.

### Claim 13 (depends on 12)

The metered dose inhaler as claimed in claim 12, wherein the canister is composed of aluminium in which the internal surfaces are uncoated.

### Claim 14 (depends on 1)

A nebuliser comprising a reservoir, wherein the reservoir contains the formulation as claimed in claim 1.

### Claim 15

A method of stabilizing an active ingredient having a functional group which is susceptible to hydrolysis and/or solvolysis, wherein the active ingredient is present in a solution formulation for inhalation, the method comprising formulating the solution formulation using at least one of a magnesium salt or a calcium salt.

### Claim 16 (depends on 1)

A method of relieving symptoms of a patient with asthma, comprising administering the formulation as claimed in claim 1 to the patient via inhalation.

### Claim 17 (depends on 16)

The method of claim 16, wherein the formulation is administered to the patient using a metered dose inhaler comprising a canister and wherein the canister contains the formulation.

### Claim 18 (depends on 16)

The method of claim 16, wherein the formulation is administered to the patient using a nebulizer comprising a reservoir and wherein the reservoir contains the formulation.

### Claim 19 (depends on 16)

The method of claim 16, wherein the amount of salt is from 0.0001 to 0.01 wt %, based on the total weight of the formulation.

### Claim 20 (depends on 16)

The method of claim 16, wherein the salt includes at least one of magnesium chloride, magnesium citrate, calcium chloride or calcium citrate.

### Claim 21 (depends on 1)

A method of relieving symptoms of a patient with chronic obstructive pulmonary disease, comprising administering the formulation as claimed in claim 1 to the patient via inhalation.

### Claim 22 (depends on 21)

The method of claim 21, wherein the formulation is administered to the patient using a metered dose inhaler comprising a canister and wherein the canister contains the formulation.

### Claim 23 (depends on 21)

The method of claim 21, wherein the formulation is administered to the patient using a nebulizer comprising a reservoir and wherein the reservoir contains the formulation.

### Claim 24 (depends on 21)

The method of claim 21, wherein the amount of salt is from 0.0001 to 0.01 wt %, based on the total weight of the formulation.

### Claim 25 (depends on 21)

The method of claim 21, wherein the salt includes at least one of magnesium chloride, magnesium citrate, calcium chloride or calcium citrate.
